BECN1 and cerebral toxoplasmosis: Moreover, treatment of mice with ocular and cerebral toxoplasmosis with Gefitinib, an EGFR TKI, results in partial reduction in parasite load and histopathology in the eye and brain that are dependent on Beclin 1 [20].